858 results on '"Hogan, William J."'
Search Results
2. Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study
3. EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
4. Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
5. Pulmonary function and long-term survival in patients with PERDS after autologous hematopoietic stem cell transplantation
6. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
7. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
8. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study
9. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
10. Adjusting diffusing capacity for anemia in patients undergoing allogeneic HCT: a comparison of two methodologies
11. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
12. A Day 14 Endpoint for Acute GVHD Clinical Trials
13. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
14. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
15. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
16. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
17. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
18. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
19. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
20. Effective treatment of low-risk acute GVHD with itacitinib monotherapy
21. High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
22. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
23. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
24. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
25. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
26. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
27. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
28. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
29. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
30. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
31. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation
32. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
33. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
34. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
35. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
36. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant
37. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation
38. Risk of relapse in patients receiving azithromycin after allogeneic HSCT
39. Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths
40. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
41. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience
42. Risk Factors and Outcomes of Nocardiosis in Hematopoietic Stem Cell Transplantation Recipients
43. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
44. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system
45. The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients
46. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
47. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function
48. Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant
49. Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
50. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.